[go: up one dir, main page]

BR112013025031A2 - antídotos anticoagulantes - Google Patents

antídotos anticoagulantes

Info

Publication number
BR112013025031A2
BR112013025031A2 BR112013025031A BR112013025031A BR112013025031A2 BR 112013025031 A2 BR112013025031 A2 BR 112013025031A2 BR 112013025031 A BR112013025031 A BR 112013025031A BR 112013025031 A BR112013025031 A BR 112013025031A BR 112013025031 A2 BR112013025031 A2 BR 112013025031A2
Authority
BR
Brazil
Prior art keywords
antidotes
anticoagulant
anticoagulant antidotes
anticoagulanges
anticoagulants
Prior art date
Application number
BR112013025031A
Other languages
English (en)
Inventor
Waterman Alisa
Ronald Sarko Christopher
Van Ryn Joanne
Canada Keith
Hauel Norbert
Copenhaver Robert
Singh Sanjaya
Litzenburger Tobias
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45876804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013025031(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112013025031A2 publication Critical patent/BR112013025031A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

antídotos anticoagulantes a presente invenção refere-se às moleculas de anticorpo junto a anticoagulanges, em particular dabigatrana e a seu uso como antídotos de tais anticoagulantes.
BR112013025031A 2011-03-30 2012-03-27 antídotos anticoagulantes BR112013025031A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161469207P 2011-03-30 2011-03-30
PCT/EP2012/055397 WO2012130834A1 (en) 2011-03-30 2012-03-27 Anticoagulant antidotes

Publications (1)

Publication Number Publication Date
BR112013025031A2 true BR112013025031A2 (pt) 2017-08-01

Family

ID=45876804

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025031A BR112013025031A2 (pt) 2011-03-30 2012-03-27 antídotos anticoagulantes

Country Status (23)

Country Link
US (2) US8821871B2 (pt)
EP (1) EP2691156A1 (pt)
JP (1) JP2014515740A (pt)
KR (1) KR20140009437A (pt)
CN (1) CN103476459A (pt)
AP (1) AP2013007046A0 (pt)
AR (1) AR085758A1 (pt)
BR (1) BR112013025031A2 (pt)
CA (1) CA2827787A1 (pt)
CL (1) CL2013002551A1 (pt)
CO (1) CO6771448A2 (pt)
EA (1) EA201301090A1 (pt)
EC (1) ECSP13012997A (pt)
IL (1) IL227653A0 (pt)
MA (1) MA34978B1 (pt)
MX (1) MX2013011092A (pt)
PE (1) PE20140964A1 (pt)
PH (1) PH12013501924A1 (pt)
SG (1) SG193552A1 (pt)
TN (1) TN2013000388A1 (pt)
TW (1) TW201302796A (pt)
UY (1) UY33994A (pt)
WO (1) WO2012130834A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3604339T (pt) 2011-01-14 2021-04-13 Univ California Anticorpos terapêuticos contra a proteína ror-1 e métodos para utilização dos mesmos
BR112014012892B1 (pt) 2011-11-29 2022-12-20 Perosphere Inc Compostos de reversão anticoagulante e composição farmacêutica compreendendo os referidos compostos
SG11201509982UA (pt) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
EP3027624B1 (en) * 2013-07-30 2018-09-12 Janssen Sciences Ireland UC Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
KR101523503B1 (ko) * 2013-09-17 2015-05-29 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
WO2015059159A1 (en) * 2013-10-25 2015-04-30 Boehringer Ingelheim International Gmbh Anticoagulant antidotes
EP2980218A1 (en) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
WO2019210270A2 (en) * 2018-04-27 2019-10-31 Seattle Children's Hospital D/B/A Seattle Children's Research Institute In vivo gene therapy using delivery of a lentiviral gene construct

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE151113T1 (de) 1992-01-23 1997-04-15 Merck Patent Gmbh Fusionsproteine von monomeren und dimeren von antikörperfragmenten
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
ATE420178T1 (de) 1992-08-21 2009-01-15 Univ Bruxelles Immunoglobuline ohne leichtkette
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
DE69405102T2 (de) 1993-06-03 1998-01-15 Therapeutic Antibodies, Inc., Nashville, Tenn. Antikoerperfragmente in therapie
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
CN1268394C (zh) 2001-01-17 2006-08-09 特鲁比昂药品公司 结合域－免疫球蛋白融合蛋白
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
KR102069498B1 (ko) 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
KR20120050457A (ko) * 2009-08-24 2012-05-18 베링거 인겔하임 인터내셔날 게엠베하 다비가트란 이텍실레이트 과다복용에 대한 활성 차콜에 의한 응급 중재
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Also Published As

Publication number Publication date
EP2691156A1 (en) 2014-02-05
US20120276123A1 (en) 2012-11-01
ECSP13012997A (es) 2013-12-31
KR20140009437A (ko) 2014-01-22
TN2013000388A1 (en) 2015-01-20
AR085758A1 (es) 2013-10-23
WO2012130834A1 (en) 2012-10-04
MX2013011092A (es) 2013-12-06
EA201301090A1 (ru) 2014-05-30
MA34978B1 (fr) 2014-03-01
NZ613543A (en) 2015-07-31
PH12013501924A1 (en) 2017-10-25
CO6771448A2 (es) 2013-10-15
US8821871B2 (en) 2014-09-02
US20140377265A1 (en) 2014-12-25
CL2013002551A1 (es) 2014-02-14
UY33994A (es) 2012-09-28
CN103476459A (zh) 2013-12-25
SG193552A1 (en) 2013-11-29
CA2827787A1 (en) 2012-10-04
IL227653A0 (en) 2013-09-30
TW201302796A (zh) 2013-01-16
JP2014515740A (ja) 2014-07-03
PE20140964A1 (es) 2014-08-17
AP2013007046A0 (en) 2013-08-31

Similar Documents

Publication Publication Date Title
BR112012018021A2 (pt) antídotos anticoagulantes.
CY1124431T1 (el) Συριγγα
BR112013025031A2 (pt) antídotos anticoagulantes
CL2015000232A1 (es) Estructura de pañal con atributos de suavidad táctil mejorados.
IL233934B (en) Cd47 antibodies, compositions comprising the same and uses thereof
BR112014030278A2 (pt) anticorpo, e, composição.
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
BR302013001738S1 (pt) Configuração aplicada em mobiliário.
BR302013000148S1 (pt) Configuração aplicada em estojo de utensílios.
BR302012000973S1 (pt) Configuração aplicada em tampo de mesa
BR112015013892A2 (pt) simulador.
FR2994808B1 (fr) Element de mobilier, notamment siege
BR112014028921A2 (pt) injetor.
UY34372A (es) Moléculas de ácido nucleico que se dirigen a rpa70 y confieren resistencia a plagas de coleópteros.
BR112013030540A2 (pt) tecido elástico.
MX2016002217A (es) Compuestos con actividad pesticida.
BR112013030892A2 (pt) artigo produzido via termoconformação.
BR112016000313A2 (pt) Botão de válvula de gaveta, gaveta de válvula, e, válvula de gaveta
EP2900693A4 (en) ADCC-mediating antibodies, combinations and uses thereof
UY35795A (es) Anticuerpos que neutralizan la actividad de dabigatran,etexilato de dabigatran y o-acilglucurónidos de dabigatran
CY1125162T1 (el) Συριγγα
FR2990870B1 (fr) Autoinjecteur.
CL2012002141S1 (es) Silla
CL2012002144S1 (es) Silla
CL2012002143S1 (es) Silla

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]